Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8O2 |
Molecular Weight | 148.1586 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C1=CC=CC=C1
InChI
InChIKey=WBYWAXJHAXSJNI-VOTSOKGWSA-N
InChI=1S/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11)/b7-6+
Molecular Formula | C9H8O2 |
Molecular Weight | 148.1586 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Cinnamic acid is a polyphenol found in cinnamon oil and used in commercial flavorings. Recent studies have shown the pharmacological properties of cinnamic acid and its derivatives, including hepatoprotective, anti-oxidant, and anti-diabetic activities. In preclinical studies cinnamic acid demonstrated to be a promising candidate for the treatment ob obesity and diabetes. The mechanism of action of cinnamic acid in obesity is explained by its ability to inhibit lipases and ACE (angiotensin-converting enzyme). However, there are several hypotesis regarding the effect of cinnamic acid in diabetes: cinnamic acid enhances glucose-induced insulin secretion, prevents palmitic acid-induced lipotoxicity, inhibits palmitic acid-induced alteration of lipogenic gene and protein expression (AMPK, SREBP-1c, FAS, ACC), inhibits DPP IV, exhibits an additive effect on the uptake of glucose, stimulates adiponectin secretion, etc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Lipid digestive enzymes Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28230764 |
|||
Target ID: P18031 Gene ID: 5770.0 Gene Symbol: PTPN1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. | 1979 Jul 1 |
|
An extracorporeal hollow-fiber reactor for phenylketonuria using immobilized phenylalanine ammonia lyase. | 1986 |
|
Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis. | 1998 Jun |
|
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. | 1999 Mar 2 |
|
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001 Mar |
|
Genetically engineered Pseudomonas: a factory of new bioplastics with broad applications. | 2001 Oct |
|
A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. | 2005 Mar |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). | 2009 May |
|
Influence of cinnamaldehyde on viral myocarditis in mice. | 2010 Aug |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Transformation of cinnamic acid from trans- to cis-form raises a notable bactericidal and synergistic activity against multiple-drug resistant Mycobacterium tuberculosis. | 2011 Jun 14 |
|
Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus. | 2011 May |
|
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). | 2011 May 1 |
|
Interaction of cinnamic acid derivatives with commercial hypoglycemic drugs on 2-deoxyglucose uptake in 3T3-L1 adipocytes. | 2011 Sep 28 |
|
Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents. | 2012 Aug |
|
Amelioration of cyclophosphamide induced myelosuppression and oxidative stress by cinnamic acid. | 2012 Feb 5 |
|
Comparative study of the possible protective effects of cinnamic acid and cinnamaldehyde on cisplatin-induced nephrotoxicity in rats. | 2013 Dec |
Patents
Sample Use Guides
In a preclinical study cinnamic acid was administered orally to rats at a dose of 5 and 10 mg/kg (diabetes model). In a preclinical model of obesity/hypertension cinnamic acid was given at 30 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19685889
To determine the effect of cinnamic acid on glucose uptake FL83B cells were suspended in HBSS
containing 5 mM glucose and 5.0 ug/mL insulin. Each 20 uL aliquot of the cell suspension was incubated with the mixture of 20 uL of 12.5 uM cinnamic acid and 20 uL of HBSS at 37 celsius degrees for 30 min with constant shaking. Glucose uptake in mouse liver FL83B cells treated with cinnamic acid (472.8 (8.9 cpm/mg of protein) is
2.3 and 2.0 times of the basal uptake value (240.6 (20.2 cpm/mg of protein), respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:36:00 GMT 2025
by
admin
on
Mon Mar 31 18:36:00 GMT 2025
|
Record UNII |
U14A832J8D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2727 (Number of products:1)
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
||
|
FDA ORPHAN DRUG |
782820
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
||
|
FDA ORPHAN DRUG |
802320
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
||
|
FDA ORPHAN DRUG |
783920
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
||
|
JECFA EVALUATION |
CINNAMIC ACID
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
210-708-3
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
ALTERNATIVE | |||
|
35697
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
1368650
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
140-10-3
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
1368649
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000090683
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
623441
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
444539
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
23248
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
187
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
m3569
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
44010
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
27386
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
CINNAMIC ACID
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
DTXSID5022489
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
SUB29136
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
1133933
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
9189
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
C029010
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
205-398-1
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
PRIMARY | |||
|
621-82-9
Created by
admin on Mon Mar 31 18:36:00 GMT 2025 , Edited by admin on Mon Mar 31 18:36:00 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Cinnamic acid content for water extract of plant leaf was 2.42+/-0.03 and plant callus was 0.76+/-0.59 as expressed as mg/100 g of dry base of extract.
For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |